LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

67%

33%

313 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2026, 22:31 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. veebr 2026, 22:18 UTC

Tulu

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. veebr 2026, 22:11 UTC

Tulu

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. veebr 2026, 21:52 UTC

Tulu

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. veebr 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. veebr 2026, 23:34 UTC

Market Talk

Tulu

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. veebr 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. veebr 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. veebr 2026, 22:45 UTC

Tulu

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. veebr 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q EPS $1.18 >NTR.T

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q Sales $5.34B >NTR.T

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q EPS $1.07 >PAAS

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q Rev $1.18B >PAAS

18. veebr 2026, 22:30 UTC

Tulu

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. veebr 2026, 22:29 UTC

Tulu

Kinross Gold 4Q EPS 75c >K.T

18. veebr 2026, 22:22 UTC

Tulu

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. veebr 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. veebr 2026, 22:16 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. veebr 2026, 22:05 UTC

Tulu

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. veebr 2026, 22:03 UTC

Tulu

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Sales $929M >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Adj EPS 67c >KGC

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Sales $2.02B >KGC

18. veebr 2026, 21:56 UTC

Tulu

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

313 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.